# Lepu Biopharma

Source: https://onco.cc/companies/lepu-biopharma/  
OnCo record `lepu-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lepu Biopharma is a China-based biotechnology company running 8 late-stage cancer trials of MRG003, Pucotenlimab and MRG006A in head and neck squamous cell carcinoma, nasopharyngeal carcinoma and hepatocellular carcinoma.

## Summary

Lepu Biopharma, based in Shanghai, China, is a biotechnology company. Lepu Biopharma is a China-based, globally focused biopharmaceutical company developing antibody-drug conjugates, oncolytic viruses and other immunotherapies for oncology. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing MRG003, Pucotenlimab, MRG006A and Cretostimogene Grenadenorepvec in head and neck squamous cell carcinoma, nasopharyngeal carcinoma, hepatocellular carcinoma and bladder & urothelial cancer. The largest, NCT06976190 (A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma), plans to enrol 446 participants. In October 2025 China's drug regulator approved MRG003 as becotatug vedotin (Meiyouheng), an antibody-drug conjugate against EGFR, for recurrent or metastatic nasopharyngeal cancer, which the company describes as the first EGFR-targeted antibody-drug conjugate approved in China. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website and the company's Hong Kong exchange filings.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Lepu Biopharma Co., Ltd.
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.lepubiopharma.com
- Ticker: 2157.HK

## Notes

- Freshened 29 October 2026 from the HKEX filings list for stock code 2157 (Lepu Biopharma). The approval was announced on 30 October 2025, which says only that the NMPA had recently granted it. Other 2025 filings were licensing of two preclinical T-cell engagers to Excalipoint and a conversion of unlisted shares to H shares; no acquisition, merger or renaming found.

## Sources

- Official website: https://www.lepubiopharma.com
- HKEX: marketing approval in China for becotatug vedotin (30 October 2025): https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1030/2025103001194.pdf
- ClinicalTrials.gov: trials led by Lepu Biopharma: https://clinicaltrials.gov/search?lead=Lepu%20Biopharma%20Co.%2C%20Ltd.

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)
- drugs: [MRG003](https://onco.cc/drugs/mrg003/), [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- trials: [A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct07138846/), [A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin](https://onco.cc/trials/nct06976190/), [A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05688605/), [A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07093970/), [A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer](https://onco.cc/trials/nct07737600/), [A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN](https://onco.cc/trials/nct05751512/), [A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma](https://onco.cc/trials/nct05126719/), [MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)](https://onco.cc/trials/nct07479485/), [Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct07586124/), [Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin](https://onco.cc/trials/nct07283835/)

---
JSON: https://onco.cc/api/v1/entities/lepu-biopharma.json